C-Path’s PKD outcomes consortium receives BAA Award for project to advance drug development tools for autosomal dominant tubulointerstitial kidney disease
TUCSON, Ariz., Sept. 19, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) focused Broad Agency Announcement (BAA) contract from the U.S. Food and Drug Administration (FDA). The overarching objective of the work supported by the BAA award is to leverage collaboration with the Wake Forest Rare Inherited Kidney Disease team and its ADTKD registry, to analyze clinical and laboratory data that will help evaluate prognosis in ADTKD and help set the stage for future clinical trials.
ADTKD only affects ...









